Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0756
D

Failure to Recommend Gradual Dose Reduction for Psychotropic Medication

Hays, Kansas Survey Completed on 07-23-2025

Penalty

27 days payment denial
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility's consultant pharmacist failed to recommend a gradual dose reduction (GDR) for a resident's psychotropic medication, specifically buspirone, despite facility policy requiring quarterly consideration of dosage reduction for such medications. The resident in question had diagnoses including anxiety disorder, hypertension, hallucinations, dementia, chronic pain, and depression, and was receiving both buspirone and bupropion for anxiety and depression. The resident's care plan included interventions for behaviors and side effects, and directed consultation with pharmacy and the physician regarding GDR when clinically appropriate. However, pharmacy reviews over several months documented no irregularities, and there was no evidence that a GDR was recommended or that the physician provided a risk versus benefit rationale for the continued use of buspirone. Observations showed the resident was able to take medications without difficulty and displayed calm behavior during interactions, though she was noted to be confused but able to answer most questions. Interviews confirmed that the pharmacist had not recommended a GDR and that the physician had not documented a rationale for ongoing use of the medication. The facility's policy required the pharmacist to report findings and make recommendations to the physician and DON, including assistance with GDR reviews, but this process was not followed for the resident's psychotropic medication regimen.

An unhandled error has occurred. Reload 🗙